LABELS · 8f55941d-f7c6-4a16-ae76-c2cd1ab7d607

Lubiprostone

Open original source → · Download preserved record

Preserved label snapshot, not confirmation of a current approved indication. Approval/withdrawal status must be checked for the exact disease, setting and regimen.

Label effective date: 2026-07-10
Captured: 2026-09-09T23:37:54.830918+00:00
Current indication reconciliation: Not reconciled

Indications and usage: exact source text

1 INDICATIONS AND USAGE Lubiprostone is a chloride channel activator indicated for the treatment of: chronic idiopathic constipation (CIC) in adults. ( 1.1 ) opioid-induced constipation (OIC) in adult patients with chronic, non-cancer pain, including patients with chronic pain related to prior cancer or its treatment who do not require frequent (e.g., weekly) opioid dosage escalation. ( 1.2 ) Limitations of Use: Effectiveness of lubiprostone in the treatment of OIC in patients taking diphenylheptane opioids (e.g., methadone) has not been established. ( 1.2 , 7.1 ) irritable bowel syndrome with constipation (IBS-C) in women ≥ 18 years old. ( 1.3 ) 1.1 Chronic Idiopathic Constipation in Adults Lubiprostone is indicated for the treatment of chronic idiopathic constipation (CIC) in adults. 1.2 Opioid-Induced Constipation in Adult Patients with Chronic Non-Cancer Pain Lubiprostone is indicated for the treatment of opioid-induced constipation (OIC) in adult patients with chronic non-cancer pain, including patients with chronic pain related to prior cancer or its treatment who do not require frequent (e.g., weekly) opioid dosage escalation. Limitations of Use: Effectiveness of lubiprostone in the treatment of opioid-induced constipation in patients taking diphenylheptane opioids (e.g., methadone) has not been established. [see Clinical Studies (14.2) ] 1.3 Irritable Bowel Syndrome with Constipation Lubiprostone is indicated for the treatment of irritable bowel syndrome with constipation (IBS-C) in women at least 18 years old.

Full extracted label fields

application numbers

NDA021908

boxed warning exact

brand names

Lubiprostone

current indication status

not_reconciled

dailymed set url

https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=006b8b6c-f0eb-4246-87da-67582984b0e4

generic names

LUBIPROSTONE

8f55941d-f7c6-4a16-ae76-c2cd1ab7d607

indications and usage exact

1 INDICATIONS AND USAGE Lubiprostone is a chloride channel activator indicated for the treatment of: chronic idiopathic constipation (CIC) in adults. ( 1.1 ) opioid-induced constipation (OIC) in adult patients with chronic, non-cancer pain, including patients with chronic pain related to prior cancer or its treatment who do not require frequent (e.g., weekly) opioid dosage escalation. ( 1.2 ) Limitations of Use: Effectiveness of lubiprostone in the treatment of OIC in patients taking diphenylheptane opioids (e.g., methadone) has not been established. ( 1.2 , 7.1 ) irritable bowel syndrome with constipation (IBS-C) in women ≥ 18 years old. ( 1.3 ) 1.1 Chronic Idiopathic Constipation in Adults Lubiprostone is indicated for the treatment of chronic idiopathic constipation (CIC) in adults. 1.2 Opioid-Induced Constipation in Adult Patients with Chronic Non-Cancer Pain Lubiprostone is indicated for the treatment of opioid-induced constipation (OIC) in adult patients with chronic non-cancer pain, including patients with chronic pain related to prior cancer or its treatment who do not require frequent (e.g., weekly) opioid dosage escalation. Limitations of Use: Effectiveness of lubiprostone in the treatment of opioid-induced constipation in patients taking diphenylheptane opioids (e.g., methadone) has not been established. [see Clinical Studies (14.2) ] 1.3 Irritable Bowel Syndrome with Constipation Lubiprostone is indicated for the treatment of irritable bowel syndrome with constipation (IBS-C) in women at least 18 years old.

indications and usage tables exact

is original packager

true

manufacturer names

Dr. Reddy's Laboratories Inc.

matched search terms

cancer

package ndcs

43598-163-60
43598-168-60

product ndcs

43598-163
43598-168

product types

HUMAN PRESCRIPTION DRUG

recent major changes exact

record type

complete_spl_indications_section_candidate

routes

ORAL

rxcuis

616578
794639

source batch

file

/private/tmp/cancer-full-research/indications/raw/labels-00500.json

meta

disclaimer

Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. We may limit or otherwise restrict your access to the API in line with our Terms of Service.

last updated

2026-09-09

license

https://open.fda.gov/license/

results

limit: 100
skip: 500
total: 830

terms

https://open.fda.gov/terms/

sha256

424ccf5bc67db0a96ee2c35ed913dd5894642716182773d81ca19cdfb9ba32f3

url

source url

https://api.fda.gov/drug/label.json?search=id%3A%228f55941d-f7c6-4a16-ae76-c2cd1ab7d607%22

spl effective date

2026-07-10

spl effective time

20260710

spl set id

006b8b6c-f0eb-4246-87da-67582984b0e4

spl version

substance names

LUBIPROSTONE

uniis

7662KG2R6K

verification flags

oncology_keyword_candidate_not_clinically_classified
spl_text_not_verified_identical_to_latest_approved_label
individual_indications_not_split_or_reconciled

Drugs@FDA application source records

application number
NDA021908
payload
all indexed label documents
Appl No
021908
Application Docs Date
2008-05-02 00:00:00
Application Docs ID
16555
Application Docs Title
0
Application Docs Type ID
2
Application Docs URL
http://www.accessdata.fda.gov/drugsatfda_docs/label/2008/021908s005lbl.pdf
Submission No
5
Submission Type
SUPPL
Appl No
021908
Application Docs Date
2011-03-04 00:00:00
Application Docs ID
16556
Application Docs Title
0
Application Docs Type ID
2
Application Docs URL
http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021908s008lbl.pdf
Submission No
8
Submission Type
SUPPL
Appl No
021908
Application Docs Date
2012-11-26 00:00:00
Application Docs ID
16557
Application Docs Title
0
Application Docs Type ID
2
Application Docs URL
http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021908s010lbl.pdf
Submission No
10
Submission Type
SUPPL
Appl No
021908
Application Docs Date
2013-04-23 00:00:00
Application Docs ID
16558
Application Docs Title
0
Application Docs Type ID
2
Application Docs URL
http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/021908s011lbl.pdf
Submission No
11
Submission Type
SUPPL
Appl No
021908
Application Docs Date
2006-02-02 00:00:00
Application Docs ID
37863
Application Docs Title
0
Application Docs Type ID
2
Application Docs URL
http://www.accessdata.fda.gov/drugsatfda_docs/label/2006/021908s000lbl.pdf
Submission No
1
Submission Type
ORIG
Appl No
021908
Application Docs Date
2007-05-29 00:00:00
Application Docs ID
37864
Application Docs Title
0
Application Docs Type ID
2
Application Docs URL
http://www.accessdata.fda.gov/drugsatfda_docs/label/2007/021908s004lbl.pdf
Submission No
4
Submission Type
SUPPL
Appl No
021908
Application Docs Date
2016-11-01 00:00:00
Application Docs ID
45750
Application Docs Title
0
Application Docs Type ID
2
Application Docs URL
http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021908s013lbl.pdf
Submission No
13
Submission Type
SUPPL
Appl No
021908
Application Docs Date
2017-08-02 00:00:00
Application Docs ID
49204
Application Docs Title
0
Application Docs Type ID
2
Application Docs URL
http://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021908s015lbl.pdf
Submission No
15
Submission Type
SUPPL
Appl No
021908
Application Docs Date
2018-04-27 00:00:00
Application Docs ID
53862
Application Docs Title
0
Application Docs Type ID
2
Application Docs URL
http://www.accessdata.fda.gov/drugsatfda_docs/label/2018/021908s016lbl.pdf
Submission No
16
Submission Type
SUPPL
Appl No
021908
Application Docs Date
2020-12-04 00:00:00
Application Docs ID
65500
Application Docs Title
0
Application Docs Type ID
2
Application Docs URL
http://www.accessdata.fda.gov/drugsatfda_docs/label/2020/021908s018lbl.pdf
Submission No
18
Submission Type
SUPPL
all submission records
Appl No
021908
Review Priority
STANDARD
Submission Class Code ID
3
Submission No
18
Submission Status
AP
Submission Status Date
2020-11-30 00:00:00
Submission Type
SUPPL
Submissions Public Notes
Appl No
021908
Review Priority
PRIORITY
Submission Class Code ID
2
Submission No
16
Submission Status
AP
Submission Status Date
2018-04-26 00:00:00
Submission Type
SUPPL
Submissions Public Notes
Appl No
021908
Review Priority
STANDARD
Submission Class Code ID
3
Submission No
15
Submission Status
AP
Submission Status Date
2017-08-01 00:00:00
Submission Type
SUPPL
Submissions Public Notes
Appl No
021908
Review Priority
STANDARD
Submission Class Code ID
3
Submission No
13
Submission Status
AP
Submission Status Date
2016-10-11 00:00:00
Submission Type
SUPPL
Submissions Public Notes
Appl No
021908
Review Priority
STANDARD
Submission Class Code ID
4
Submission No
12
Submission Status
AP
Submission Status Date
2013-08-19 00:00:00
Submission Type
SUPPL
Submissions Public Notes
Appl No
021908
Review Priority
PRIORITY
Submission Class Code ID
2
Submission No
11
Submission Status
AP
Submission Status Date
2013-04-19 00:00:00
Submission Type
SUPPL
Submissions Public Notes
Appl No
021908
Review Priority
STANDARD
Submission Class Code ID
3
Submission No
10
Submission Status
AP
Submission Status Date
2012-11-26 00:00:00
Submission Type
SUPPL
Submissions Public Notes
Appl No
021908
Review Priority
STANDARD
Submission Class Code ID
3
Submission No
8
Submission Status
AP
Submission Status Date
2011-02-24 00:00:00
Submission Type
SUPPL
Submissions Public Notes
Appl No
021908
Review Priority
UNKNOWN
Submission Class Code ID
2
Submission No
5
Submission Status
AP
Submission Status Date
2008-04-29 00:00:00
Submission Type
SUPPL
Submissions Public Notes
Appl No
021908
Review Priority
STANDARD
Submission Class Code ID
3
Submission No
4
Submission Status
AP
Submission Status Date
2007-05-16 00:00:00
Submission Type
SUPPL
Submissions Public Notes
Appl No
021908
Review Priority
STANDARD
Submission Class Code ID
7
Submission No
1
Submission Status
AP
Submission Status Date
2006-01-31 00:00:00
Submission Type
ORIG
Submissions Public Notes
application number
NDA021908
approval interpretation
Application linkage and approved submission are not indication-level current approval verification
current indication status
not_reconciled
drugsfda url
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021908
has approved submission record
true
latest approved submission date
2020-11-30
latest label selection rule
max FDA ApplicationDocsDate, including all ties; posting date is not approval date and latest indexed document may be incomplete
latest posted label documents
Appl No
021908
Application Docs Date
2020-12-04 00:00:00
Application Docs ID
65500
Application Docs Title
0
Application Docs Type ID
2
Application Docs URL
http://www.accessdata.fda.gov/drugsatfda_docs/label/2020/021908s018lbl.pdf
Submission No
18
Submission Type
SUPPL
official application record
Appl No
021908
Appl Public Notes
Appl Type
NDA
Sponsor Name
SUCAMPO PHARMA LLC
openfda application present
true
products
Active Ingredient
LUBIPROSTONE
Appl No
021908
Drug Name
AMITIZA
Form
CAPSULE;ORAL
Product No
001
Reference Drug
1
Reference Standard
1
Strength
24MCG
marketing status
Prescription
Active Ingredient
LUBIPROSTONE
Appl No
021908
Drug Name
AMITIZA
Form
CAPSULE;ORAL
Product No
002
Reference Drug
1
Reference Standard
0
Strength
8MCG
marketing status
Prescription

Source passages and status connections

Passage classifications are automated and are not treatment recommendations. Connections apply only to their recorded indication scope.

Passage 1 · positive indication candidate

application numbers

NDA021908

brand names

Lubiprostone

classification reasons

explicit_positive_indication_predicate
no_tumor_directed_keyword_in_positive_statement

clinical review status

pending

content role

positive_indication_candidate

context span

end: 349
end exclusive: true
exact text: 1 INDICATIONS AND USAGE Lubiprostone is a chloride channel activator indicated for the treatment of: chronic idiopathic constipation (CIC) in adults. ( 1.1 ) opioid-induced constipation (OIC) in adult patients with chronic, non-cancer pain, including patients with chronic pain related to prior cancer or its treatment who do not require frequent (e
label id: 8f55941d-f7c6-4a16-ae76-c2cd1ab7d607
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: cfc947dd7799305cf1c884f33cf50db34059d02e07cd07e8b399b1cae324c549
start: 0

current approval status

not_reconciled

duplicate text group

dup-6cf5a4ca612654b36073

extraction review status

automated_candidate_pending_source_review

generic names

LUBIPROSTONE

ind-span-e6489882d00b07b04667

label id

8f55941d-f7c6-4a16-ae76-c2cd1ab7d607

positive predicate support span

end: 78
end exclusive: true
exact text: is a chloride channel activator indicated
label id: 8f55941d-f7c6-4a16-ae76-c2cd1ab7d607
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: cfc947dd7799305cf1c884f33cf50db34059d02e07cd07e8b399b1cae324c549
start: 37

qualifier mentions

context exact
the treatment of: chronic idiopathic constipation (CIC) in adults.
kind
age
polarity
not_inferred
span
end
148
end exclusive
true
exact text
adults
label id
8f55941d-f7c6-4a16-ae76-c2cd1ab7d607
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
cfc947dd7799305cf1c884f33cf50db34059d02e07cd07e8b399b1cae324c549
start
142

regulatory links

schema version

0.1.0

source batch sha256

424ccf5bc67db0a96ee2c35ed913dd5894642716182773d81ca19cdfb9ba32f3

source defined aliases

source span

end: 149
end exclusive: true
exact text: 1 INDICATIONS AND USAGE Lubiprostone is a chloride channel activator indicated for the treatment of: chronic idiopathic constipation (CIC) in adults.
label id: 8f55941d-f7c6-4a16-ae76-c2cd1ab7d607
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: cfc947dd7799305cf1c884f33cf50db34059d02e07cd07e8b399b1cae324c549
start: 0

source url

https://api.fda.gov/drug/label.json?search=id%3A%228f55941d-f7c6-4a16-ae76-c2cd1ab7d607%22

spl effective date

2026-07-10

spl set id

006b8b6c-f0eb-4246-87da-67582984b0e4

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

non_oncology_or_unclear_candidate

Passage 2 · positive indication candidate

application numbers

NDA021908

brand names

Lubiprostone

classification reasons

inherited_predicate_from_same_label_section_requires_review
supportive_or_complication_use_words

clinical review status

pending

content role

positive_indication_candidate

context span

end: 587
end exclusive: true
exact text: 1 INDICATIONS AND USAGE Lubiprostone is a chloride channel activator indicated for the treatment of: chronic idiopathic constipation (CIC) in adults. ( 1.1 ) opioid-induced constipation (OIC) in adult patients with chronic, non-cancer pain, including patients with chronic pain related to prior cancer or its treatment who do not require frequent (e.g., weekly) opioid dosage escalation. ( 1.2 ) Limitations of Use: Effectiveness of lubiprostone in the treatment of OIC in patients taking diphenylheptane opioids (e.g., methadone) has not been established. ( 1.2 , 7.1 ) irritable bowel
label id: 8f55941d-f7c6-4a16-ae76-c2cd1ab7d607
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: cfc947dd7799305cf1c884f33cf50db34059d02e07cd07e8b399b1cae324c549
start: 0

current approval status

not_reconciled

duplicate text group

dup-651d6db59bc0ad3d3c3f

extraction review status

automated_candidate_pending_source_review

generic names

LUBIPROSTONE

ind-span-34f44cb3017318ac6c31

label id

8f55941d-f7c6-4a16-ae76-c2cd1ab7d607

positive predicate support span

end: 78
end exclusive: true
exact text: is a chloride channel activator indicated
label id: 8f55941d-f7c6-4a16-ae76-c2cd1ab7d607
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: cfc947dd7799305cf1c884f33cf50db34059d02e07cd07e8b399b1cae324c549
start: 37

qualifier mentions

context exact
( 1.1 ) opioid-induced constipation (OIC) in adult patients with chronic, non-cancer pain, including patients with chro
kind
age
polarity
not_inferred
span
end
209
end exclusive
true
exact text
adult patients
label id
8f55941d-f7c6-4a16-ae76-c2cd1ab7d607
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
cfc947dd7799305cf1c884f33cf50db34059d02e07cd07e8b399b1cae324c549
start
195

regulatory links

schema version

0.1.0

source batch sha256

424ccf5bc67db0a96ee2c35ed913dd5894642716182773d81ca19cdfb9ba32f3

source defined aliases

source span

end: 387
end exclusive: true
exact text: ( 1.1 ) opioid-induced constipation (OIC) in adult patients with chronic, non-cancer pain, including patients with chronic pain related to prior cancer or its treatment who do not require frequent (e.g., weekly) opioid dosage escalation.
label id: 8f55941d-f7c6-4a16-ae76-c2cd1ab7d607
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: cfc947dd7799305cf1c884f33cf50db34059d02e07cd07e8b399b1cae324c549
start: 150

source url

https://api.fda.gov/drug/label.json?search=id%3A%228f55941d-f7c6-4a16-ae76-c2cd1ab7d607%22

spl effective date

2026-07-10

spl set id

006b8b6c-f0eb-4246-87da-67582984b0e4

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

supportive_care_candidate

Passage 3 · limitation of use

application numbers

NDA021908

brand names

Lubiprostone

classification reasons

negative_or_not_established_clause

clinical review status

pending

content role

limitation_of_use

context span

end: 756
end exclusive: true
exact text: IC) in adult patients with chronic, non-cancer pain, including patients with chronic pain related to prior cancer or its treatment who do not require frequent (e.g., weekly) opioid dosage escalation. ( 1.2 ) Limitations of Use: Effectiveness of lubiprostone in the treatment of OIC in patients taking diphenylheptane opioids (e.g., methadone) has not been established. ( 1.2 , 7.1 ) irritable bowel syndrome with constipation (IBS-C) in women ≥ 18 years old. ( 1.3 ) 1.1 Chronic Idiopathic Constipation in Adults Lubiprostone is indicated for the treatment of chronic
label id: 8f55941d-f7c6-4a16-ae76-c2cd1ab7d607
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: cfc947dd7799305cf1c884f33cf50db34059d02e07cd07e8b399b1cae324c549
start: 188

current approval status

not_reconciled

duplicate text group

dup-cba6607816da4a41610c

extraction review status

automated_candidate_pending_source_review

generic names

LUBIPROSTONE

ind-span-f5b906c927f355fcac22

label id

8f55941d-f7c6-4a16-ae76-c2cd1ab7d607

positive predicate support span

Source null

qualifier mentions

context exact
nt of OIC in patients taking diphenylheptane opioids (e.g., methadone) has not been established.
kind
biomarker
polarity
not_inferred
span
end
555
end exclusive
true
exact text
methadone) has not been established
label id
8f55941d-f7c6-4a16-ae76-c2cd1ab7d607
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
cfc947dd7799305cf1c884f33cf50db34059d02e07cd07e8b399b1cae324c549
start
520

regulatory links

schema version

0.1.0

source batch sha256

424ccf5bc67db0a96ee2c35ed913dd5894642716182773d81ca19cdfb9ba32f3

source defined aliases

source span

end: 556
end exclusive: true
exact text: ( 1.2 ) Limitations of Use: Effectiveness of lubiprostone in the treatment of OIC in patients taking diphenylheptane opioids (e.g., methadone) has not been established.
label id: 8f55941d-f7c6-4a16-ae76-c2cd1ab7d607
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: cfc947dd7799305cf1c884f33cf50db34059d02e07cd07e8b399b1cae324c549
start: 388

source url

https://api.fda.gov/drug/label.json?search=id%3A%228f55941d-f7c6-4a16-ae76-c2cd1ab7d607%22

spl effective date

2026-07-10

spl set id

006b8b6c-f0eb-4246-87da-67582984b0e4

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

not_applicable

Passage 4 · unclassified context

application numbers

NDA021908

brand names

Lubiprostone

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 846
end exclusive: true
exact text: kly) opioid dosage escalation. ( 1.2 ) Limitations of Use: Effectiveness of lubiprostone in the treatment of OIC in patients taking diphenylheptane opioids (e.g., methadone) has not been established. ( 1.2 , 7.1 ) irritable bowel syndrome with constipation (IBS-C) in women ≥ 18 years old. ( 1.3 ) 1.1 Chronic Idiopathic Constipation in Adults Lubiprostone is indicated for the treatment of chronic idiopathic constipation (CIC) in adults. 1.2 Opioid-Induced Constipation in Adult Patients
label id: 8f55941d-f7c6-4a16-ae76-c2cd1ab7d607
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: cfc947dd7799305cf1c884f33cf50db34059d02e07cd07e8b399b1cae324c549
start: 357

current approval status

not_reconciled

duplicate text group

dup-e0145f18949abadd758f

extraction review status

automated_candidate_pending_source_review

generic names

LUBIPROSTONE

ind-span-ee177b41b719d58afe0b

label id

8f55941d-f7c6-4a16-ae76-c2cd1ab7d607

positive predicate support span

Source null

qualifier mentions

context exact
ritable bowel syndrome with constipation (IBS-C) in women ≥ 18 years old.
kind
age
polarity
not_inferred
span
end
641
end exclusive
true
exact text
18 years
label id
8f55941d-f7c6-4a16-ae76-c2cd1ab7d607
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
cfc947dd7799305cf1c884f33cf50db34059d02e07cd07e8b399b1cae324c549
start
633

regulatory links

schema version

0.1.0

source batch sha256

424ccf5bc67db0a96ee2c35ed913dd5894642716182773d81ca19cdfb9ba32f3

source defined aliases

source span

end: 646
end exclusive: true
exact text: ( 1.2 , 7.1 ) irritable bowel syndrome with constipation (IBS-C) in women ≥ 18 years old.
label id: 8f55941d-f7c6-4a16-ae76-c2cd1ab7d607
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: cfc947dd7799305cf1c884f33cf50db34059d02e07cd07e8b399b1cae324c549
start: 557

source url

https://api.fda.gov/drug/label.json?search=id%3A%228f55941d-f7c6-4a16-ae76-c2cd1ab7d607%22

spl effective date

2026-07-10

spl set id

006b8b6c-f0eb-4246-87da-67582984b0e4

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Passage 5 · unclassified context

application numbers

NDA021908

brand names

Lubiprostone

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 854
end exclusive: true
exact text: n the treatment of OIC in patients taking diphenylheptane opioids (e.g., methadone) has not been established. ( 1.2 , 7.1 ) irritable bowel syndrome with constipation (IBS-C) in women ≥ 18 years old. ( 1.3 ) 1.1 Chronic Idiopathic Constipation in Adults Lubiprostone is indicated for the treatment of chronic idiopathic constipation (CIC) in adults. 1.2 Opioid-Induced Constipation in Adult Patients with Ch
label id: 8f55941d-f7c6-4a16-ae76-c2cd1ab7d607
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: cfc947dd7799305cf1c884f33cf50db34059d02e07cd07e8b399b1cae324c549
start: 447

current approval status

not_reconciled

duplicate text group

dup-02bcce754371f4fe2ae1

extraction review status

automated_candidate_pending_source_review

generic names

LUBIPROSTONE

ind-span-54fc2adad96f8c6590ea

label id

8f55941d-f7c6-4a16-ae76-c2cd1ab7d607

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

424ccf5bc67db0a96ee2c35ed913dd5894642716182773d81ca19cdfb9ba32f3

source defined aliases

source span

end: 654
end exclusive: true
exact text: ( 1.3 )
label id: 8f55941d-f7c6-4a16-ae76-c2cd1ab7d607
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: cfc947dd7799305cf1c884f33cf50db34059d02e07cd07e8b399b1cae324c549
start: 647

source url

https://api.fda.gov/drug/label.json?search=id%3A%228f55941d-f7c6-4a16-ae76-c2cd1ab7d607%22

spl effective date

2026-07-10

spl set id

006b8b6c-f0eb-4246-87da-67582984b0e4

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Passage 6 · positive indication candidate

application numbers

NDA021908

brand names

Lubiprostone

classification reasons

explicit_positive_indication_predicate
no_tumor_directed_keyword_in_positive_statement

clinical review status

pending

content role

positive_indication_candidate

context span

end: 996
end exclusive: true
exact text: eatment of OIC in patients taking diphenylheptane opioids (e.g., methadone) has not been established. ( 1.2 , 7.1 ) irritable bowel syndrome with constipation (IBS-C) in women ≥ 18 years old. ( 1.3 ) 1.1 Chronic Idiopathic Constipation in Adults Lubiprostone is indicated for the treatment of chronic idiopathic constipation (CIC) in adults. 1.2 Opioid-Induced Constipation in Adult Patients with Chronic Non-Cancer Pain Lubiprostone is indicated for the treatment of opioid-induced constipation (OIC) in adult patients with chronic non-canc
label id: 8f55941d-f7c6-4a16-ae76-c2cd1ab7d607
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: cfc947dd7799305cf1c884f33cf50db34059d02e07cd07e8b399b1cae324c549
start: 455

current approval status

not_reconciled

duplicate text group

dup-0c54faaf394ab293815e

extraction review status

automated_candidate_pending_source_review

generic names

LUBIPROSTONE

ind-span-efcc7ee8c20097e63445

label id

8f55941d-f7c6-4a16-ae76-c2cd1ab7d607

positive predicate support span

end: 726
end exclusive: true
exact text: is indicated
label id: 8f55941d-f7c6-4a16-ae76-c2cd1ab7d607
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: cfc947dd7799305cf1c884f33cf50db34059d02e07cd07e8b399b1cae324c549
start: 714

qualifier mentions

context exact
1.1 Chronic Idiopathic Constipation in Adults Lubiprostone is indicated for the treatment of chronic idio
kind
age
polarity
not_inferred
span
end
700
end exclusive
true
exact text
Adults
label id
8f55941d-f7c6-4a16-ae76-c2cd1ab7d607
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
cfc947dd7799305cf1c884f33cf50db34059d02e07cd07e8b399b1cae324c549
start
694
context exact
r the treatment of chronic idiopathic constipation (CIC) in adults.
kind
age
polarity
not_inferred
span
end
795
end exclusive
true
exact text
adults
label id
8f55941d-f7c6-4a16-ae76-c2cd1ab7d607
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
cfc947dd7799305cf1c884f33cf50db34059d02e07cd07e8b399b1cae324c549
start
789

regulatory links

schema version

0.1.0

source batch sha256

424ccf5bc67db0a96ee2c35ed913dd5894642716182773d81ca19cdfb9ba32f3

source defined aliases

source span

end: 796
end exclusive: true
exact text: 1.1 Chronic Idiopathic Constipation in Adults Lubiprostone is indicated for the treatment of chronic idiopathic constipation (CIC) in adults.
label id: 8f55941d-f7c6-4a16-ae76-c2cd1ab7d607
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: cfc947dd7799305cf1c884f33cf50db34059d02e07cd07e8b399b1cae324c549
start: 655

source url

https://api.fda.gov/drug/label.json?search=id%3A%228f55941d-f7c6-4a16-ae76-c2cd1ab7d607%22

spl effective date

2026-07-10

spl set id

006b8b6c-f0eb-4246-87da-67582984b0e4

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

non_oncology_or_unclear_candidate

Passage 7 · positive indication candidate

application numbers

NDA021908

brand names

Lubiprostone

classification reasons

explicit_positive_indication_predicate
supportive_or_complication_use_words

clinical review status

pending

content role

positive_indication_candidate

context span

end: 1351
end exclusive: true
exact text: ith constipation (IBS-C) in women ≥ 18 years old. ( 1.3 ) 1.1 Chronic Idiopathic Constipation in Adults Lubiprostone is indicated for the treatment of chronic idiopathic constipation (CIC) in adults. 1.2 Opioid-Induced Constipation in Adult Patients with Chronic Non-Cancer Pain Lubiprostone is indicated for the treatment of opioid-induced constipation (OIC) in adult patients with chronic non-cancer pain, including patients with chronic pain related to prior cancer or its treatment who do not require frequent (e.g., weekly) opioid dosage escalation. Limitations of Use: Effectiveness of lubiprostone in the treatment of opioid-induced constipation in patients taking diphenylheptane opioids (e.g., methadone) has not been established. [see Clinical
label id: 8f55941d-f7c6-4a16-ae76-c2cd1ab7d607
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: cfc947dd7799305cf1c884f33cf50db34059d02e07cd07e8b399b1cae324c549
start: 597

current approval status

not_reconciled

duplicate text group

dup-19737c5d6b9a6c441392

extraction review status

automated_candidate_pending_source_review

generic names

LUBIPROSTONE

ind-span-b9b22749bb0b7da3f02f

label id

8f55941d-f7c6-4a16-ae76-c2cd1ab7d607

positive predicate support span

end: 901
end exclusive: true
exact text: is indicated
label id: 8f55941d-f7c6-4a16-ae76-c2cd1ab7d607
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: cfc947dd7799305cf1c884f33cf50db34059d02e07cd07e8b399b1cae324c549
start: 889

qualifier mentions

context exact
1.2 Opioid-Induced Constipation in Adult Patients with Chronic Non-Cancer Pain Lubiprostone is indicated for
kind
age
polarity
not_inferred
span
end
846
end exclusive
true
exact text
Adult Patients
label id
8f55941d-f7c6-4a16-ae76-c2cd1ab7d607
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
cfc947dd7799305cf1c884f33cf50db34059d02e07cd07e8b399b1cae324c549
start
832
context exact
d for the treatment of opioid-induced constipation (OIC) in adult patients with chronic non-cancer pain, including patients with chron
kind
age
polarity
not_inferred
span
end
974
end exclusive
true
exact text
adult patients
label id
8f55941d-f7c6-4a16-ae76-c2cd1ab7d607
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
cfc947dd7799305cf1c884f33cf50db34059d02e07cd07e8b399b1cae324c549
start
960

regulatory links

schema version

0.1.0

source batch sha256

424ccf5bc67db0a96ee2c35ed913dd5894642716182773d81ca19cdfb9ba32f3

source defined aliases

source span

end: 1151
end exclusive: true
exact text: 1.2 Opioid-Induced Constipation in Adult Patients with Chronic Non-Cancer Pain Lubiprostone is indicated for the treatment of opioid-induced constipation (OIC) in adult patients with chronic non-cancer pain, including patients with chronic pain related to prior cancer or its treatment who do not require frequent (e.g., weekly) opioid dosage escalation.
label id: 8f55941d-f7c6-4a16-ae76-c2cd1ab7d607
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: cfc947dd7799305cf1c884f33cf50db34059d02e07cd07e8b399b1cae324c549
start: 797

source url

https://api.fda.gov/drug/label.json?search=id%3A%228f55941d-f7c6-4a16-ae76-c2cd1ab7d607%22

spl effective date

2026-07-10

spl set id

006b8b6c-f0eb-4246-87da-67582984b0e4

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

supportive_care_candidate

Passage 8 · limitation of use

application numbers

NDA021908

brand names

Lubiprostone

classification reasons

negative_or_not_established_clause

clinical review status

pending

content role

limitation_of_use

context span

end: 1544
end exclusive: true
exact text: OIC) in adult patients with chronic non-cancer pain, including patients with chronic pain related to prior cancer or its treatment who do not require frequent (e.g., weekly) opioid dosage escalation. Limitations of Use: Effectiveness of lubiprostone in the treatment of opioid-induced constipation in patients taking diphenylheptane opioids (e.g., methadone) has not been established. [see Clinical Studies (14.2) ] 1.3 Irritable Bowel Syndrome with Constipation Lubiprostone is indicated for the treatment of irritable bowel syndrome with constipation (IBS-C) in women at least 18 years old.
label id: 8f55941d-f7c6-4a16-ae76-c2cd1ab7d607
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: cfc947dd7799305cf1c884f33cf50db34059d02e07cd07e8b399b1cae324c549
start: 952

current approval status

not_reconciled

duplicate text group

dup-0811de0649eccb26da52

extraction review status

automated_candidate_pending_source_review

generic names

LUBIPROSTONE

ind-span-8ba8a3292b5276dea598

label id

8f55941d-f7c6-4a16-ae76-c2cd1ab7d607

positive predicate support span

Source null

qualifier mentions

context exact
stipation in patients taking diphenylheptane opioids (e.g., methadone) has not been established. [see Clinical Studies (14.2) ]
kind
biomarker
polarity
not_inferred
span
end
1335
end exclusive
true
exact text
methadone) has not been established
label id
8f55941d-f7c6-4a16-ae76-c2cd1ab7d607
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
cfc947dd7799305cf1c884f33cf50db34059d02e07cd07e8b399b1cae324c549
start
1300

regulatory links

schema version

0.1.0

source batch sha256

424ccf5bc67db0a96ee2c35ed913dd5894642716182773d81ca19cdfb9ba32f3

source defined aliases

source span

end: 1367
end exclusive: true
exact text: Limitations of Use: Effectiveness of lubiprostone in the treatment of opioid-induced constipation in patients taking diphenylheptane opioids (e.g., methadone) has not been established. [see Clinical Studies (14.2) ]
label id: 8f55941d-f7c6-4a16-ae76-c2cd1ab7d607
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: cfc947dd7799305cf1c884f33cf50db34059d02e07cd07e8b399b1cae324c549
start: 1152

source url

https://api.fda.gov/drug/label.json?search=id%3A%228f55941d-f7c6-4a16-ae76-c2cd1ab7d607%22

spl effective date

2026-07-10

spl set id

006b8b6c-f0eb-4246-87da-67582984b0e4

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

not_applicable

Passage 9 · positive indication candidate

application numbers

NDA021908

brand names

Lubiprostone

classification reasons

explicit_positive_indication_predicate
no_tumor_directed_keyword_in_positive_statement

clinical review status

pending

content role

positive_indication_candidate

context span

end: 1544
end exclusive: true
exact text: se: Effectiveness of lubiprostone in the treatment of opioid-induced constipation in patients taking diphenylheptane opioids (e.g., methadone) has not been established. [see Clinical Studies (14.2) ] 1.3 Irritable Bowel Syndrome with Constipation Lubiprostone is indicated for the treatment of irritable bowel syndrome with constipation (IBS-C) in women at least 18 years old.
label id: 8f55941d-f7c6-4a16-ae76-c2cd1ab7d607
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: cfc947dd7799305cf1c884f33cf50db34059d02e07cd07e8b399b1cae324c549
start: 1168

current approval status

not_reconciled

duplicate text group

dup-dcd67bfea4a58cae7c8a

extraction review status

automated_candidate_pending_source_review

generic names

LUBIPROSTONE

ind-span-da8cf4691b21aaf1fcc3

label id

8f55941d-f7c6-4a16-ae76-c2cd1ab7d607

positive predicate support span

end: 1440
end exclusive: true
exact text: is indicated
label id: 8f55941d-f7c6-4a16-ae76-c2cd1ab7d607
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: cfc947dd7799305cf1c884f33cf50db34059d02e07cd07e8b399b1cae324c549
start: 1428

qualifier mentions

context exact
bowel syndrome with constipation (IBS-C) in women at least 18 years old.
kind
age
polarity
not_inferred
span
end
1539
end exclusive
true
exact text
18 years
label id
8f55941d-f7c6-4a16-ae76-c2cd1ab7d607
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
cfc947dd7799305cf1c884f33cf50db34059d02e07cd07e8b399b1cae324c549
start
1531

regulatory links

schema version

0.1.0

source batch sha256

424ccf5bc67db0a96ee2c35ed913dd5894642716182773d81ca19cdfb9ba32f3

source defined aliases

source span

end: 1544
end exclusive: true
exact text: 1.3 Irritable Bowel Syndrome with Constipation Lubiprostone is indicated for the treatment of irritable bowel syndrome with constipation (IBS-C) in women at least 18 years old.
label id: 8f55941d-f7c6-4a16-ae76-c2cd1ab7d607
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: cfc947dd7799305cf1c884f33cf50db34059d02e07cd07e8b399b1cae324c549
start: 1368

source url

https://api.fda.gov/drug/label.json?search=id%3A%228f55941d-f7c6-4a16-ae76-c2cd1ab7d607%22

spl effective date

2026-07-10

spl set id

006b8b6c-f0eb-4246-87da-67582984b0e4

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

non_oncology_or_unclear_candidate

Preserved source evidence · Not medical advice